Trial Profile
A Randomized Withdrawal Double-blind Study of Etanercept Monotherapy Compared to Methotrexate Monotherapy for Maintenance of Remission in Subjects With Rheumatoid Arthritis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Dec 2022
Price :
$35
*
At a glance
- Drugs Etanercept (Primary) ; Methotrexate
- Indications Rheumatoid arthritis
- Focus Registrational; Therapeutic Use
- Acronyms SEAM-RA
- Sponsors Amgen
- 24 Oct 2022 Results(n=253) assessing patient-reported outcomes rheumatoid arthritis following medication withdrawal and disease worsening changes in patients with published in the JCR: Journal of Clinical Rheumatology
- 05 Jun 2021 Results presented at the 22nd Annual Congress of the European League Against Rheumatism
- 18 Nov 2020 Primary endpoint (Simplified Disease Activity Index (SDAI) remission ( 3.3) at week 48) has been met.